CA2458279A1 - Modulation du stockage de vitamines - Google Patents

Modulation du stockage de vitamines Download PDF

Info

Publication number
CA2458279A1
CA2458279A1 CA002458279A CA2458279A CA2458279A1 CA 2458279 A1 CA2458279 A1 CA 2458279A1 CA 002458279 A CA002458279 A CA 002458279A CA 2458279 A CA2458279 A CA 2458279A CA 2458279 A1 CA2458279 A1 CA 2458279A1
Authority
CA
Canada
Prior art keywords
vitamin
tocopherol
phosphate derivative
phosphate
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002458279A
Other languages
English (en)
Inventor
Simon Michael West
David Kannar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vital Health Sciences Pty Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/AU2001/001206 external-priority patent/WO2002026238A1/fr
Priority claimed from AU2002951045A external-priority patent/AU2002951045A0/en
Application filed by Individual filed Critical Individual
Publication of CA2458279A1 publication Critical patent/CA2458279A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode permettant d'augmenter les taux de vitamine stockée pour une vitamine sélectionnée dans le groupe comprenant le tocophérol, le rétinol, la vitamine K1 et des mélanges de ceux-ci, dans un tissu cible d'un sujet. Cette méthode consiste à administrer au sujet une dose efficace d'un dérivé phosphate de cette vitamine de manière à provoquer une accumulation de vitamine stockée dans le tissu cible.
CA002458279A 2001-09-26 2002-09-26 Modulation du stockage de vitamines Abandoned CA2458279A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/AU2001/001206 WO2002026238A1 (fr) 2000-09-26 2001-09-26 Supplements a base de derive phosphate
AUPCT/AU01/01206 2001-09-26
AU2002951045 2002-08-27
AU2002951045A AU2002951045A0 (en) 2002-08-27 2002-08-27 Method of supplementing nascent endogenous storage forms
PCT/AU2002/001321 WO2003026673A1 (fr) 2001-09-26 2002-09-26 Modulation du stockage de vitamines

Publications (1)

Publication Number Publication Date
CA2458279A1 true CA2458279A1 (fr) 2003-04-03

Family

ID=25613914

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002458279A Abandoned CA2458279A1 (fr) 2001-09-26 2002-09-26 Modulation du stockage de vitamines

Country Status (5)

Country Link
EP (1) EP1429782A4 (fr)
JP (1) JP2005515969A (fr)
CA (1) CA2458279A1 (fr)
MX (1) MXPA04001779A (fr)
WO (1) WO2003026673A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
WO2004064831A1 (fr) * 2003-01-17 2004-08-05 Vital Health Sciences Pty Ltd Composes possedant des proprietes antiproliferatives
CA2557354C (fr) * 2004-03-03 2013-05-07 Vital Health Sciences Pty Ltd. Formulations alcaloides
EP2269650A3 (fr) * 2004-08-03 2012-05-16 Vital Health Sciences Pty Ltd. Support pour l'administration entérale
WO2006092024A1 (fr) * 2005-03-03 2006-09-08 Vital Health Sciences Pty Ltd Composés ayant des propriétés anticancéreuses
CN101132789A (zh) * 2005-03-03 2008-02-27 生命健康科学有限公司 具有降脂性能的化合物
NZ565049A (en) 2005-06-17 2012-02-24 Vital Health Sciences Pty Ltd A carrier comprising one or more DI and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
EP2531047A4 (fr) 2010-02-05 2014-03-19 Phosphagenics Ltd Vecteur comprenant du phosphate de tocophéryle non neutralisé
EP2531219A4 (fr) * 2010-02-05 2015-01-14 Phosphagenics Ltd Composition de support
EP2552486B1 (fr) 2010-03-30 2020-08-12 Phosphagenics Limited Timbre transdermique
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
JP6882321B2 (ja) 2015-12-09 2021-06-02 フォスファージニクス リミテッド 医薬製剤
AU2017381395A1 (en) 2016-12-21 2019-06-20 Phosphagenics Limited Process

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2854631B2 (ja) * 1989-11-21 1999-02-03 千寿製薬株式会社 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤
US5114957A (en) * 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
FR2679904A1 (fr) * 1991-08-01 1993-02-05 Lvmh Rech Utilisation d'un phosphate de tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, ou pharmaceutiques et compositions ainsi obtenues.
US5643597A (en) * 1991-08-01 1997-07-01 Lvmh Recherche Use of a tocopherol phosphate or one of its derivatives for the preparation of cosmetic or pharmaceutical compositions and compositions so obtained
AU3662093A (en) * 1992-02-14 1993-09-03 Robert Lamb Phosphate derivatives of vitamin e to protect cells from effects of aging and injury
JPH05286848A (ja) * 1992-04-10 1993-11-02 Senju Pharmaceut Co Ltd 浴用剤
FR2715565B1 (fr) * 1994-01-31 1996-03-15 Oreal Composition cosmétique ou dermatologique stabilisée contenant plusieurs précurseurs d'un même actif pour maximaliser sa libération, son utilisation.
JP3362501B2 (ja) * 1994-04-28 2003-01-07 千寿製薬株式会社 角膜障害治療剤
JPH10155429A (ja) * 1996-11-27 1998-06-16 Showa Denko Kk 動物に対するビタミンｅ供給方法および動物用トコフェロールリン酸エステル又はその塩類組成物
JPH1143436A (ja) * 1997-07-25 1999-02-16 Showa Denko Kk 末梢血流障害予防・治療剤
US5776915A (en) * 1997-08-12 1998-07-07 Clarion Pharmaceuticals Inc. Phosphocholines of retinoids
JP3950216B2 (ja) * 1997-12-26 2007-07-25 日本メナード化粧品株式会社 皮膚外用剤
WO2002026238A1 (fr) * 2000-09-26 2002-04-04 Vital Health Sciences Pty Ltd. Supplements a base de derive phosphate

Also Published As

Publication number Publication date
EP1429782A1 (fr) 2004-06-23
EP1429782A4 (fr) 2005-02-02
JP2005515969A (ja) 2005-06-02
MXPA04001779A (es) 2004-05-31
WO2003026673A1 (fr) 2003-04-03

Similar Documents

Publication Publication Date Title
US20040241225A1 (en) Modulation of vitamin storage
US5198432A (en) Method of preventing chlorohydrocarbon toxicity using sterol derivatives
US8173145B2 (en) Formulation containing phosphate derivatives of electron transfer agents
US9789127B2 (en) N-acyl-phosphatidyl-ethanolamines and/or mixtures of N-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
CA2458279A1 (fr) Modulation du stockage de vitamines
US20090186856A1 (en) Micronutrient phosphates as dietary and health supplements
Gross et al. Seven day oral supplementation with Cardax TM (disodium disuccinate astaxanthin) provides significant cardioprotection and reduces oxidative stress in rats
JP2010241818A (ja) 電子移動剤のホスフェート誘導体を含有する処方
US5610180A (en) Ionizable congeners of aromatic and aliphatic alcohols as anti-leukemia agents
WO2005099739A1 (fr) Chromoproteines dibenzo-alpha-pyrone oxygenees
Khan et al. Phospholipids: a novel adjuvant in herbal drug delivery systems
AU2002333019B2 (en) Modulation of vitamin storage
ZA200401126B (en) Modulation of vitamin storage.
AU2002333019A1 (en) Modulation of vitamin storage
US7033612B2 (en) Composition and method for treating age-related disorders
CA1117041A (fr) Complexe lipoproteique normalisant l'efficacite de la vitamine e et des antioxydants de synthese
AU2002322163B2 (en) Micronutrient phosphates as dietary and health supplements
CH635749A5 (en) Lipoprotein complex which regularises the efficacy of vitamin E and synthetic antioxidants
AU2002214820A1 (en) Formulation containing phosphate derivatives of electron transfer agents
AU2002322163A1 (en) Micronutrient phosphates as dietary and health supplements

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20080926